Clinical Report: Long-Term Outcomes and Disease Progression in Ulcerative Colitis

Overview

This study evaluates the long-term clinical outcomes and risk factors for a disabling disease course in patients with moderate-to-severe ulcerative colitis (UC) over a 5-year follow-up.

Background

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that significantly impacts patients' quality of life. The rising incidence and prevalence of UC in Korea is documented, and this study aims to describe the natural history of moderate-to-severe UC in this demographic.

Data Highlights

No numerical data is available in the source material.

Key Findings

• The incidence of UC in Korea increased from 0.33 per 100,000 in 1986 to 6.58 per 100,000 in 2015.
• Prevalence of UC more than doubled from 31.6 per 100,000 in 2010 to 65.5 per 100,000 in 2018.
• 58.2% of patients achieved remission or mild endoscopic activity at 1 year follow-up.
• No colectomy or mortality was observed in the initial year of the study.
• Long-term outcomes indicate a risk for disabling disease despite favorable early results.

Clinical Implications

Healthcare professionals should be aware of the increasing incidence of UC in Korea and the distinct clinical patterns in Asian populations. Long-term monitoring of patients with moderate-to-severe UC is essential to manage potential disease progression effectively.

Conclusion

Continued research is necessary to inform treatment strategies and improve patient care.

Related Resources & Content

1. Journal of Gastroenterology, 2017 -- Long-term Adalimumab Therapy for Japanese Individuals with Moderate to Severe Ulcerative Colitis: A Four-Year Study
2. Journal of Gastroenterology, 2024 -- Effects of Prompt Intensive Intervention on Long-Term Biochemical Marker Trends in Inflammatory Bowel Disease
3. Evaluating Anorectal Function in Individuals with Recurrent Ulcerative Colitis
4. Frontiers in Medicine, 2026 -- Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
5. Advancing IBD Diagnosis and Monitoring: The Latest ECCO-ESGAR-ESP-IBUS Guidelines
6. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
7. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
8. https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617
9. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - ScienceDirect
10. Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis - a network meta-analysis of randomized trials - PubMed
11. Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team - PMC